Form 8-K - Current report:
SEC Accession No. 0001193125-25-145405
Filing Date
2025-06-24
Accepted
2025-06-24 09:27:01
Documents
17
Period of Report
2025-06-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d34398d8k.htm   iXBRL 8-K 32765
2 EX-5.1 d34398dex51.htm EX-5.1 7857
3 EX-10.1 d34398dex101.htm EX-10.1 109328
4 EX-99.1 d34398dex991.htm EX-99.1 13452
8 GRAPHIC g34398g0624051102656.jpg GRAPHIC 2607
9 GRAPHIC g34398g0624084058997.jpg GRAPHIC 5373
  Complete submission text file 0001193125-25-145405.txt   338122

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA cadl-20250623.xsd EX-101.SCH 2853
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE cadl-20250623_lab.xml EX-101.LAB 18737
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cadl-20250623_pre.xml EX-101.PRE 11709
19 EXTRACTED XBRL INSTANCE DOCUMENT d34398d8k_htm.xml XML 3764
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 251066920
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)